BAX Earnings Prediction
The chart below shows how BAX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BAX sees a +1.60% change in stock price 10 days leading up to the earnings, and a -0.54% change 10 days following the report. On the earnings day itself, the stock moves by -1.52%. This data can give you a slight idea of what to expect for the next quarter's release.
BAX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
2.70B
-27.21%
-29.20%
Gross Margin
38.35%
24.63%
1.51%
Operating Margin
11.15%
-5.59%
19.38%
Net Margin
2.26%
63.77%
-127.70%
EPS
0.27
-94.52%
-143.55%
No Data Available
BAX Earnings Analysis
Baxter International Inc. Corporation (BAX.N) Earnings Conference Call
Positive
Third Quarter Sales Growth: Total company third quarter 2024 sales grew 4% on both a reported and constant currency basis, in line with prior guidance, with all Baxter segments increasing year-over-year.
Earnings Per Share Beat: Total company adjusted earnings per share was $0.80, ahead of the guidance range of $0.77 to $0.79 per share, driven by top line strength and improved supply chain efficiency.
Medical Products Growth: Medical Products & Therapies segment led with 7% growth at both reported and constant currency rates, fueled by strong demand across the portfolio, particularly for the Novum IQ platform.
Healthcare Segment Growth: Healthcare Systems & Technologies segment grew 1%, driven by strong US performance in the Care & Connectivity Solutions division, particularly for patient support systems products, which increased low double-digits.
Kidney Care Segment Growth: Kidney Care segment grew 4% on a reported basis and 5% at constant currency, driven by demand and pricing for acute therapies and peritoneal dialysis products.
Negative
Hurricane Sales Impact: 1. Hurricane Impact on Sales: Baxter expects a negative impact of approximately $200 million on total company fourth quarter sales due to Hurricane Helene, including an estimated $150 million to $160 million impact on Medical Products & Therapies sales.
Operating Margin Decline: 2. Decline in Operating Margins: Adjusted operating margins from continuing operations are expected to decline by 90 to 100 basis points in 2024, primarily due to stranded costs impacting margins by approximately 250 basis points.
Healthcare Systems Decline: 3. Weakness in Healthcare Systems & Technologies: The Healthcare Systems & Technologies segment is now expected to decline low-single-digits, reflecting ongoing softness in the US Primary Care market and a difficult comparison to the prior year.
Stranded Costs Effect: 4. Stranded Costs Impact: Stranded costs negatively impacted Baxter's results in the quarter, with an approximate $55 million headwind affecting adjusted operating margins by 240 basis points.
Pharmaceutical Sales Decline: 5. Pharmaceutical Segment Challenges: The Pharmaceuticals segment experienced a high-single-digit decline in Injectables & Anesthesia sales, driven by supply constraints and phasing of selected sales into the fourth quarter.
BAX FAQs
How does BAX typically perform around its earnings report dates?
Is Baxter International Inc. (BAX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BAX Earning Call Sentiment
Baxter International Inc. (BAX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BAX.N
1.14%Positive
The earnings call reflects strong financial performance with 4% sales growth and 18% EPS growth YoY. The company has raised its full-year sales and EPS guidance, indicating optimism. The Q&A reveals confidence in operational improvements and margin expansion. However, some uncertainties remain regarding IV fluid shortage impacts and margin targets. Overall, the positive financial metrics, raised guidance, and strategic initiatives suggest a positive stock price movement, likely in the 2% to 8% range.
